Galmed Pharmaceuticals Ltd Total Liabilities
Galmed Pharmaceuticals Ltd total liabilities. Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has total liabilities worth $5.54 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Galmed Pharmaceuticals Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Galmed Pharmaceuticals Ltd (2012–2025)
Total liabilities of Galmed Pharmaceuticals Ltd from 2012 to 2025. This chart illustrates how Galmed Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Galmed Pharmaceuticals Ltd (GLMD) investment intensity to see how much of total assets are deployed in long-term investments.
Galmed Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ARGO GOLD INC.
F:P3U
|
Germany | €1.76 Million |
|
Bumi Citra Permai Tbk
JK:BCIP
|
Indonesia | Rp383.81 Billion |
|
FUTURE METALS NL
F:3R10
|
Germany | €381.80K |
|
Adslot Ltd
AU:ADS
|
Australia | AU$9.92 Million |
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
Indonesia | Rp797.31 Billion |
|
Sdcl Energy Efficiency Income Trust PLC
LSE:SEIT
|
UK | GBX2.00 Million |
|
OCEAN-GEOLOOP AS NK -01
F:FQ4
|
Germany | €60.66 Million |
|
Sungshin Cement Co Ltd
KO:004985
|
Korea | ₩762.60 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Galmed Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Galmed Pharmaceuticals Ltd assets under control.
Liquidity & Leverage Metrics
Galmed Pharmaceuticals Ltd Total Liabilities Ratios Explained
Galmed Pharmaceuticals Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galmed Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galmed Pharmaceuticals Ltd (2012–2025)
The table below shows the annual total liabilities of Galmed Pharmaceuticals Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.85 Million | +30.92% |
| 2024-12-31 | $2.17 Million | -20.98% |
| 2023-12-31 | $2.75 Million | -12.36% |
| 2022-12-31 | $3.14 Million | -48.62% |
| 2021-12-31 | $6.11 Million | -25.77% |
| 2020-12-31 | $8.23 Million | +12.93% |
| 2019-12-31 | $7.29 Million | +169.25% |
| 2018-12-31 | $2.71 Million | -29.68% |
| 2017-12-31 | $3.85 Million | -28.41% |
| 2016-12-31 | $5.38 Million | +97.76% |
| 2015-12-31 | $2.72 Million | +79.05% |
| 2014-12-31 | $1.52 Million | -28.29% |
| 2013-12-31 | $2.12 Million | -22.77% |
| 2012-12-31 | $2.74 Million | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more